BRPI0708965B8 - composição farmacêutica de metilnaltrexona - Google Patents

composição farmacêutica de metilnaltrexona

Info

Publication number
BRPI0708965B8
BRPI0708965B8 BRPI0708965A BRPI0708965A BRPI0708965B8 BR PI0708965 B8 BRPI0708965 B8 BR PI0708965B8 BR PI0708965 A BRPI0708965 A BR PI0708965A BR PI0708965 A BRPI0708965 A BR PI0708965A BR PI0708965 B8 BRPI0708965 B8 BR PI0708965B8
Authority
BR
Brazil
Prior art keywords
methylnaltrexone
pharmaceutical composition
lessen
severity
formulations
Prior art date
Application number
BRPI0708965A
Other languages
English (en)
Inventor
Luther Ofslager Christian
Fawzi Mahdi
Bazhina Natalyia
M Shah Syed
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39033508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0708965(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0708965A2 publication Critical patent/BRPI0708965A2/pt
Publication of BRPI0708965B1 publication Critical patent/BRPI0708965B1/pt
Publication of BRPI0708965B8 publication Critical patent/BRPI0708965B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)

Abstract

composição farmacêutica de metilnaltrexona. a presente invenção fornece formulações parenterais que obtêm liberação eficaz de composições de metilnaltrexona. as formulações fornecidas são úteis para prevenir, tratar, atrasar, diminuir ou reduzir a severidade de efeitos colaterais que resultam do uso de analgésicos opioides.
BRPI0708965A 2006-08-04 2007-08-03 composição farmacêutica de metilnaltrexona BRPI0708965B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83557406P 2006-08-04 2006-08-04
US60/835,574 2006-08-04
PCT/US2007/017430 WO2008019115A2 (en) 2006-08-04 2007-08-03 Formulations for parenteral delivery of compounds and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0708965A2 BRPI0708965A2 (pt) 2011-06-28
BRPI0708965B1 BRPI0708965B1 (pt) 2020-01-07
BRPI0708965B8 true BRPI0708965B8 (pt) 2021-05-25

Family

ID=39033508

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0708965A BRPI0708965B8 (pt) 2006-08-04 2007-08-03 composição farmacêutica de metilnaltrexona

Country Status (25)

Country Link
US (7) US20080070975A1 (pt)
EP (1) EP2046388B1 (pt)
JP (1) JP5356231B2 (pt)
KR (1) KR20090040248A (pt)
CN (2) CN102846613A (pt)
AR (1) AR063471A1 (pt)
AU (1) AU2007281984B8 (pt)
BR (1) BRPI0708965B8 (pt)
CA (1) CA2646901C (pt)
EC (1) ECSP088752A (pt)
ES (1) ES2655863T3 (pt)
GT (1) GT200800185A (pt)
HN (1) HN2008001464A (pt)
IL (2) IL194182A (pt)
MX (1) MX2008011993A (pt)
NO (1) NO343701B1 (pt)
NZ (1) NZ597260A (pt)
PE (1) PE20080741A1 (pt)
PH (1) PH12013500801A1 (pt)
PL (1) PL2046388T3 (pt)
RU (1) RU2539387C2 (pt)
SG (1) SG174030A1 (pt)
TW (1) TWI489984B (pt)
WO (1) WO2008019115A2 (pt)
ZA (1) ZA200808203B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
CA2811272C (en) † 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TW200815451A (en) * 2006-08-04 2008-04-01 Wyeth Corp 6-carboxy-normorphinan derivatives, synthesis and uses thereof
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP2565195B1 (en) * 2007-03-29 2015-05-06 Wyeth LLC Peripheral opioid receptor and antagonists and uses thereof
PL2137191T3 (pl) * 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
JP2010522756A (ja) * 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
AU2008349873B2 (en) * 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
WO2009099410A1 (en) * 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r)-8-keto-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
AU2016201221B2 (en) * 2008-09-30 2017-08-10 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
AU2013203119B2 (en) * 2008-09-30 2015-12-03 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
NZ713967A (en) * 2009-07-28 2017-01-27 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
CN102918039B (zh) 2010-03-11 2017-06-09 惠氏有限责任公司 甲基纳曲酮的口服制剂和亲脂盐
LT2616064T (lt) 2010-10-21 2019-11-25 Rtu Pharmaceuticals Llc Parengtos naudoti ketorolako kompozicijos
CN102525911B (zh) * 2012-03-20 2013-09-18 南京臣功制药股份有限公司 一种溴甲纳曲酮注射液及其制备方法
CN103239452A (zh) * 2013-01-25 2013-08-14 辽宁亿灵科创生物医药科技有限公司 一种溴甲基纳曲酮药物组合物
AU2014230834B9 (en) 2013-03-14 2017-08-31 Fresenius Kabi Deutschland Gmbh Injectable morphine formulations
WO2014140097A1 (en) 2013-03-14 2014-09-18 Becton Dickinson France S.A.S. Packaging system for oxygen-sensitive drugs
EP3027174B1 (en) * 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
JP6686013B2 (ja) 2014-10-17 2020-04-22 サリックス ファーマスーティカルズ，インコーポレーテッド 腫瘍の進行を減弱させるためのメチルナルトレキソンの使用
CN105769755A (zh) * 2014-12-23 2016-07-20 北大方正集团有限公司 一种溴甲纳曲酮注射液及其制备方法
US10695402B2 (en) * 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
CN110960486B (zh) * 2018-09-29 2022-05-13 北京凯因科技股份有限公司 一种溴甲纳曲酮注射液组合物
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤
CN111303093A (zh) * 2020-02-21 2020-06-19 重庆医药高等专科学校 一种溴甲纳曲酮杂质的制备方法
US12514939B2 (en) 2024-02-14 2026-01-06 Alpha-9 Oncology, Inc. Stable radiopharmaceutical compositions and uses thereof
CN120241599A (zh) * 2025-05-12 2025-07-04 北京化药科创医药科技发展有限公司 一种耐受终端灭菌的溴甲纳曲酮注射液及其制备方法

Family Cites Families (293)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1420015B1 (de) 1959-10-16 1971-08-26 Boehringer Sohn Ingelheim 2'-Hydroxy-5,9-dimethyl-6,7-benzomorphane
GB1202148A (en) 1968-03-06 1970-08-12 Sankyo Co Pharmaceutical compositions
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3714159A (en) 1971-03-30 1973-01-30 Janssen Pharmaceutica Nv 2,2-diaryl-4-(4'-aryl-4'-hydroxy-piper-idino)-butyramides
US3884916A (en) 1971-03-30 1975-05-20 Janssen Pharmaceutica Nv 2,2-Diaryl-4-(4-aryl-4-hydroxy-piperidino)-butyramides
US4025652A (en) 1975-03-31 1977-05-24 William H. Rorer, Inc. Amidinoureas
US4326074A (en) 1972-09-22 1982-04-20 William H. Rorer, Inc. Amidinoureas
US3937801A (en) 1973-07-10 1976-02-10 American Home Products Corporation Reducing the incidence of gastrointestinal side effects during the treatment of inflammatory conditions with antiinflammatory drugs
US4060635A (en) 1975-03-31 1977-11-29 William H. Rorer, Inc. Amidinoureas for treating diarrhea
US4203920A (en) 1975-03-31 1980-05-20 William H. Rorer, Inc. Amidinoureas
US4066654A (en) 1975-04-16 1978-01-03 G. D. Searle & Co. 1-triarylalkyl-4-phenyl-4-piperidine carboxylic acids and derivatives
US4072686A (en) 1975-04-16 1978-02-07 G. D. Searle & Co. 1-(3,3,3-Triarylalkyl)-4-phenyl-piperidinealkanols
US3996214A (en) 1976-02-23 1976-12-07 G. D. Searle & Co. 5-(1,1-Diphenyl-4-(cyclic amino) but-2-trans-en-1-yl)-2-alkyl-1,3,4-oxadiazoles and intermediates thereto
US4013668A (en) 1976-03-10 1977-03-22 G. D. Searle & Co. 5-(1,1-diphenyl-3-(5- or 6-hydroxy-2-azabicyclo(2.2.2)oct-2-yl)propyl)-2-alkyl-1,3,4-oxadiazoles and related compounds
US4012393A (en) 1976-03-22 1977-03-15 G. D. Searle & Co. 2-[5-(CYCLIC AMINO) ETHYL-10,11-DIHYDRO-5H-dibenzo[a,d]-cyclohepten-5- yl]-5
US4115400A (en) 1976-05-27 1978-09-19 Eli Lilly And Company 1-Azoniabicyclo[3.1.0]hexanes
GB1593191A (en) 1977-03-23 1981-07-15 Reckitt & Colmann Prod Ltd Derivatives of morphine
US4125531A (en) 1977-04-18 1978-11-14 G. D. Searle & Co. 2-Substituted-1-azabicyclo[2.2.2]octanes
US4069223A (en) 1977-05-02 1978-01-17 G. D. Searle & Co. 4-Aminomethyl-1-(3,3,3-triarylpropyl)-4-arylpiperidine and derivatives thereof
US4116963A (en) 1977-05-23 1978-09-26 G.D. Searle & Co. 3,3,3-triarylalkyl-4-phenylalkyl-4-hydroxy piperidines and related compounds
US4194045A (en) 1977-12-27 1980-03-18 G. D. Searle & Co. 1-(3,3-Diaryl-3-oxadiazolalkyl)-4-phenyl-4-piperidinomethanols and related compounds
IT1096665B (it) 1978-06-14 1985-08-26 Tecnofarmaci Spa Composizione farmaceutica per la terapia di stati di frigidita' ed impotenza
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
JPS5535031A (en) 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
US4311833A (en) 1979-03-06 1982-01-19 Daicel Chemical Industries Ltd. Process for preparing ethylcarboxymethylcellulose
US4277605A (en) 1980-03-07 1981-07-07 Bristol-Myers Company Chemical compounds
US4322426A (en) 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4466968A (en) 1980-11-24 1984-08-21 Dermall, Ltd. Method for prophylaxis or treatment of emesis and nausea
US4427676A (en) 1980-12-19 1984-01-24 John Wyeth & Brother Ltd. Thiomorpholine derivatives
US4377568A (en) 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
EP0103636B1 (en) 1982-03-16 1990-09-12 Rockefeller University Use of opium antagonists for the manufacture of medicaments for controlling gastrointestinal dysmotility
US4870084A (en) 1982-03-16 1989-09-26 Pfizer Inc. Bicyclic benzo fused pyran compounds used for nausea treatment and prevention
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US4430327A (en) 1982-05-18 1984-02-07 Eli Lilly And Company Method for treating pregnant females for pain and anxiety
US4457907A (en) 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
US4533739A (en) 1982-10-12 1985-08-06 G. D. Searle & Co. 2-[(Aminophenyl and amidophenyl)amino]-1-azacycloalkanes having antidiarrheal activity
US4518433A (en) 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
JPS601128A (ja) 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
US4462839A (en) 1983-06-16 1984-07-31 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4689332A (en) 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US4666716A (en) 1984-09-04 1987-05-19 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof
JPS6229515A (ja) 1985-07-30 1987-02-07 Shinjiro Tsuji 硬カプセル剤のフイルムコ−テイング方法
JPH0676314B2 (ja) 1985-09-30 1994-09-28 花王株式会社 坐剤基剤及び坐剤
US4824853A (en) 1985-10-11 1989-04-25 Janssen Pharmaceutica N.V. α,α-diaryl-4-aryl-4-hydroxy-1-piperidinebutanamide, N-oxides and method of treating diarrhea
US4730048A (en) 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4806556A (en) 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
EP0306575B1 (en) 1987-09-10 1992-07-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (en) 1986-03-14 1992-03-10 Edward David Weil Thermally stable diphosphonate-type flame retardant additive for plastics
DE3609073C2 (de) 1986-03-18 1995-08-10 Hans J Prof Dr Rer Nat Schmitt Meßeinrichtung zur nichtinvasiven Feststellung peripherer Abfluß- und Durchflußstörungen in menschlichen Extremitäten
US4990521A (en) 1986-07-03 1991-02-05 Janssen Pharmaceutica 4-(aroylamino)piperidine-butanimide derivatives
DE3777658D1 (de) 1986-08-28 1992-04-23 Enzacor Pty Ltd Tierwachstumserreger.
US5597564A (en) 1986-08-28 1997-01-28 Enzacor Properties Limited Method of administering a microgranular preparation to the intestinal region of animals
US4888346A (en) 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
US4765978A (en) 1986-12-16 1988-08-23 Schering Corporation Novel vaginal suppository
FR2609632B1 (fr) 1987-01-21 1991-03-29 Shelly Marc Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
NL8700842A (pt) 1987-04-10 1988-11-01 Duphar Int Res
US4891379A (en) 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
IL83086A (en) 1987-07-06 1991-03-10 Teva Pharma Stable,injectable solutions of vincristine salts
US4857833A (en) 1987-08-27 1989-08-15 Teradyne, Inc. Diagnosis of faults on circuit board
CA1315689C (en) 1987-09-03 1993-04-06 Leon I. Goldberg Quarternary derivatives of noroxymorphone which relieve nausea and emesis
DE3744053A1 (de) 1987-12-21 1989-07-13 Schering Ag Fungizides mittel mit synergistischer wirkung
US4912114A (en) 1988-03-18 1990-03-27 Sandoz Ltd. Morphinan derivatives
SG64368A1 (en) 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
JPH0653683B2 (ja) 1988-07-14 1994-07-20 ザ ロックフェラー ユニバーシティ 慢性痛あるいは慢性咳を治療する経口用組成物
EP0352361A1 (en) 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4999342A (en) 1988-08-16 1991-03-12 Ortho Pharmaceutical Corporation Long lasting contraceptive suppository composition and methods of use
US4863928A (en) 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5116868A (en) 1989-05-03 1992-05-26 The Johns Hopkins University Effective ophthalmic irrigation solution
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US4965269A (en) 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5236947A (en) 1990-02-28 1993-08-17 Jouveinal S.A. Propanamines, their pharmacological properties and their application as an antidiarrheal
JPH0813748B2 (ja) 1990-04-23 1996-02-14 帝國製薬株式会社 大腸崩壊性ポリペプチド系経口製剤
DK0527879T3 (da) 1990-05-11 1997-07-14 Pfizer Synergistiske terapeutiske præparater og fremgangsmåder.
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
JP3160862B2 (ja) 1990-11-15 2001-04-25 雪印乳業株式会社 骨強化食品、飼料及び医薬
JPH04230625A (ja) 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
JPH06505747A (ja) 1991-02-25 1994-06-30 トラスティーズ・オブ・ボストン・ユニバーシティ 多動運動障害を変調するアヘン剤受容体アンタゴニスト
US5250542A (en) 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
CA2064373C (en) 1991-03-29 2005-08-23 Buddy Eugene Cantrell Piperidine derivatives
US5270328A (en) 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5220017A (en) 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
DK0590060T3 (da) 1991-06-21 1998-05-11 Univ Cincinnati Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5614219A (en) 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
US5256154A (en) 1992-01-31 1993-10-26 Sterling Winthrop, Inc. Pre-filled plastic syringes and containers and method of terminal sterilization thereof
JPH05213763A (ja) 1992-02-10 1993-08-24 Sanwa Kagaku Kenkyusho Co Ltd 易吸収活性化カルシウム製剤
GB2272375B (en) 1992-04-10 1996-02-14 Vnii Med Polimerov Pharmaceutical composition
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
USRE36547E (en) 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5512578A (en) 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
GB9221707D0 (en) * 1992-10-15 1992-12-02 Smithkline Beecham Plc Pharmaceutical composition
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
CA2086631C (en) 1992-12-22 1998-10-06 J. Gabriel Michael Oral administration of immunologically active biomolecules and other therapeutic proteins
DE4303214A1 (de) 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
US5585348A (en) 1993-02-10 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5391372A (en) 1993-06-28 1995-02-21 Campbell; Elizabeth Methods of treating colic and founder in horses
NZ268969A (en) 1993-07-23 1997-06-24 Toray Industries Morphinan derivatives and pharmaceutical compositions
US5358970A (en) * 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB2281205A (en) 1993-08-24 1995-03-01 Euro Celtique Sa Oral opioid analgesic
SE9303744D0 (sv) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
US5434171A (en) 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
EP0758403B1 (en) 1994-05-05 1998-06-24 Beckman Instruments, Inc. Oligonucleotide repeat arrays
IT1269826B (it) 1994-05-24 1997-04-15 Paolo Minoia Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5614222A (en) 1994-10-25 1997-03-25 Kaplan; Milton R. Stable aqueous drug suspensions and methods for preparation thereof
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US6096763A (en) 1995-02-23 2000-08-01 Merck & Co., Inc. α1a adrenergic receptor antagonists
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
GB9517001D0 (en) 1995-08-18 1995-10-18 Denny William Enediyne compounds
US5804595A (en) 1995-12-05 1998-09-08 Regents Of The University Of Minnesota Kappa opioid receptor agonists
ES2168121T7 (es) 1995-12-21 2013-09-24 Syngenta Participations Ag Derivados de ácido 3-amino-2-mercaptobenzoico y procedimientos para su preparación
ES2208870T3 (es) 1996-02-15 2004-06-16 Janssen Pharmaceutica N.V. Uso de antagonistas del receptor 5ht4 para resolver los efectos gastrointestinales de los inhibidores de la reabsorcion de serotonina.
DE69709646T2 (de) 1996-03-12 2002-08-14 Alza Corp., Palo Alto Zusammensetzung und dosisform mit einem opioid-antagonisten
US6136780A (en) 1996-03-29 2000-10-24 The Penn State Research Foundation Control of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (ζ) receptor
US20040024006A1 (en) 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
JP3648864B2 (ja) 1996-08-28 2005-05-18 三菱自動車工業株式会社 希薄燃焼内燃機関
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US20010036469A1 (en) 1997-01-13 2001-11-01 Gooberman Lance L. Opiate antagonist implant and process for preparation therefor
WO1998035679A1 (de) 1997-02-14 1998-08-20 Gödecke Aktiengesellschaft Stabilisierung von naloxonhydrochlorid
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
HU9701081D0 (en) 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
US6525038B1 (en) 1997-06-24 2003-02-25 Werner Kreutz Synergistic compositions for the selective control of tumor tissue
US6353004B1 (en) 1997-07-14 2002-03-05 Adolor Coporation Peripherally acting anti-pruritic opiates
US6096764A (en) 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
US6099853A (en) 1997-09-04 2000-08-08 Protein Express Vaginal suppository vaccine for urogenital infections
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
AU2003204844B2 (en) 1997-11-03 2007-06-07 Arch Development Corporation Use of methylnaltrexone and related compounds
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
EP0913152B1 (de) 1997-11-03 2001-12-19 Stada Arzneimittel Ag Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum
US6777534B1 (en) 1997-12-09 2004-08-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
JP2001526228A (ja) 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド作動薬／拮抗薬の併用
EP0930334A1 (en) 1998-01-16 1999-07-21 Quest International B.V. Polysaccharide conjugate capable of binding cellulose
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
GB9802251D0 (en) 1998-02-03 1998-04-01 Ciba Geigy Ag Organic compounds
WO1999051246A1 (en) 1998-04-03 1999-10-14 Ajinomoto Co., Inc. Antitumor agents
DE19818802A1 (de) 1998-04-27 1999-10-28 Dresden Arzneimittel Stabile Mitoxantron-Lösungen
US6359111B1 (en) 1998-05-28 2002-03-19 Neorx Corporation Opioid receptor targeting
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
US20010010919A1 (en) 1998-10-13 2001-08-02 David K. Grandy Opioid antagonists and methods of their use
EP1141711A1 (en) 1999-01-05 2001-10-10 Unilever Plc Binding of antibody fragments to solid supports
DK1144616T4 (da) 1999-01-19 2009-03-30 Unilever Nv Fremgangsmåde til fremstilling af antistoffragmenter
CA2293008A1 (en) 1999-01-28 2000-07-28 Hong Qi Premixed alatrofloxacin injectable compositions
CA2361678A1 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
US6194382B1 (en) 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
JP4049477B2 (ja) 1999-03-23 2008-02-20 大鵬薬品工業株式会社 副作用軽減剤
CA2370351A1 (en) 1999-04-22 2000-11-02 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
US7129265B2 (en) 1999-04-23 2006-10-31 Mason R Preston Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
US6171620B1 (en) 1999-04-27 2001-01-09 Health Research, Inc. Method of enhancing the efficacy of anti-tumor agents
AU4564200A (en) 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US20020068712A1 (en) 1999-07-23 2002-06-06 Troy Stevens Use of decreasing levels of functional transient receptor potential gene product
US20030105121A1 (en) 1999-07-27 2003-06-05 Bernard Bihari Method of preventing lipodystrophy syndrome or reversing a pre-existing syndrome in HIV-infected patients being treated with antiretroviral agents
IL147920A0 (en) 1999-08-02 2002-08-14 Keygene Nv Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants
WO2001013909A2 (en) 1999-08-25 2001-03-01 Cooper Barrett R Compositions and methods for treating opiate intolerance
ES2226886T3 (es) 1999-08-31 2005-04-01 Grunenthal Gmbh Forma de administracion de accion retardada que contiene sacarinato de tramadol.
CZ2002947A3 (cs) * 1999-09-29 2002-08-14 The Procter & Gamble Company Kapalný prostředek, nejlépe orální prostředek se zlepąenou stabilitou a způsob přípravy
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
ES2226933T3 (es) 1999-11-01 2005-04-01 John Rhodes Composicion para tratar el estreñimiento y el sindrome del intestino irritable.
EP1097720B1 (en) 1999-11-04 2005-10-12 Institut Gustave Roussy Antiviral agent in combination with radiation therapy for use in treatment of cancer
ES2278647T3 (es) 1999-11-29 2007-08-16 Adolor Corporation Nuevos procedimientos y composiciones que comprenden opioides y antagonistas de opioides.
US6384044B1 (en) 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
WO2001041705A2 (en) 1999-11-29 2001-06-14 Adolor Corporation Novel methods for the treatment and prevention of dizziness and pruritus
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
MXPA02005336A (es) 1999-11-29 2003-01-28 Adolor Corp Metodos novedosos para el tratamiento y prevencion del ileo.
US6911455B2 (en) 1999-12-22 2005-06-28 Smithkline Beecham Corporation Methods for preparing pharmaceutical formulations
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
US20010046968A1 (en) 2000-03-23 2001-11-29 Zagon Ian S. Opioid growth factor modulates angiogenesis
US6967075B2 (en) 2000-04-07 2005-11-22 Schering Corporation HCV replicase complexes
JP2004515455A (ja) 2000-05-05 2004-05-27 ペイン・セラピューティクス・インコーポレイテッド オピオイドアンタゴニスト組成物および投薬形態
EP1296714B1 (en) 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
EP1175905A1 (en) 2000-07-24 2002-01-30 Societe Des Produits Nestle S.A. Nutritional Composition
FI116089B (sv) 2000-07-27 2005-09-15 Johan Tore Karlstroem Anordning och förfaranden vid reglar
RU2241462C2 (ru) 2000-07-28 2004-12-10 Ф. Хоффманн-Ля Рош Аг Новая фармацевтическая композиция
NZ507152A (en) 2000-09-27 2001-06-29 Hiltive Pty Ltd Wall cladding assembly with cladding having recesses along opposite sides to engage with flanges of support members
US6630462B2 (en) 2000-11-17 2003-10-07 Adolor Corporation Delta agonist analgesics
AU2002219707A1 (en) 2000-12-04 2002-06-18 Primagen B.V. Testing endosymbiont cellular organelles and compounds identifiable therewith
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
AU3938402A (en) 2000-12-13 2002-06-24 Lilly Co Eli Chronic treatment regimen using glucagon-like insulinotropic peptides
KR100405161B1 (ko) 2000-12-14 2003-11-12 신풍제약주식회사 록소프로펜 함유 근육주사제 조성물
GB0100115D0 (en) 2001-01-04 2001-02-14 Alchemia Pty Ltd Delivery systems
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
ATE450265T1 (de) 2001-03-23 2009-12-15 Shire Canada Inc Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
US20040242523A1 (en) 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
US20040136908A1 (en) 2001-04-09 2004-07-15 Olson William C. Anti-cd19 immunotoxins
NZ528994A (en) 2001-04-26 2006-02-24 Control Delivery Sys Inc Sustained release drug delivery system containing codrugs
US20030022909A1 (en) 2001-06-05 2003-01-30 University Of Chicago Use of methylnaltrexone to treat immune suppression
WO2003005952A2 (en) 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
US8012517B2 (en) 2001-08-31 2011-09-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels with extracts of noni juice Morinda citrifolia
ES2654819T3 (es) 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
US20030144312A1 (en) 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
WO2003037365A1 (en) 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
EP1451174B1 (en) 2001-11-29 2010-08-18 Schering Corporation Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers
EP1458710A4 (en) 2001-12-21 2005-04-20 Merck & Co Inc Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
US20050011468A1 (en) 2002-02-04 2005-01-20 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
CA2475305A1 (en) 2002-02-04 2004-02-19 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
US7074825B2 (en) 2002-03-07 2006-07-11 Huanbiao Mo Composition and method for treating cancer
KR20040098660A (ko) 2002-03-14 2004-11-20 유로-셀티크 소시에떼 아노뉨 날트렉손 하이드로클로라이드 조성물
CA2480814A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US7355081B2 (en) 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
ATE510553T1 (de) 2002-05-17 2011-06-15 Univ Texas Beta-2-glycoprotein 1 als angiogenesehemmer
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US6986901B2 (en) 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions
US20040010997A1 (en) 2002-07-17 2004-01-22 Oren Close Guides to align masonry walls defining apertures, and methods of use
US7160913B2 (en) 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
US7691374B2 (en) 2002-10-23 2010-04-06 Health Research, Inc. Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody
EP1562953B1 (en) 2002-11-08 2009-09-30 Mallinckrodt Inc. Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
JP2004183371A (ja) 2002-12-04 2004-07-02 Inax Corp ユニットバスの補強構造
WO2004054511A2 (en) 2002-12-13 2004-07-01 The Regents Of The University Of California Analgesic combination comprising nalbuphine
WO2004054569A1 (en) 2002-12-16 2004-07-01 Council Of Scientific And Industrial Research Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings
US7396943B2 (en) 2003-03-07 2008-07-08 Eli Lilly And Company Opioid receptor antagonists
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
EP1638607A1 (en) 2003-04-08 2006-03-29 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
US6992193B2 (en) 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
JP2007501866A (ja) 2003-06-13 2007-02-01 マイクロバイア インコーポレイテッド 胃腸疾患の治療のための方法および組成物
AU2003903387A0 (en) 2003-07-02 2003-07-17 Sirtex Medical Limited Combination therapy for treatment of neoplasia
EP1682006A4 (en) 2003-10-29 2011-01-26 Physiosonics Inc METHOD AND DEVICE FOR DETERMINING A MIDDLE LINE OF AN ULTRASONIC LIQUID FLOW
SE0303135D0 (sv) 2003-11-25 2003-11-25 Lipocore Holding Ab Controlled food effect composition
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
CA2550071A1 (en) 2003-12-19 2005-07-07 Schering Corporation Pharmaceutical compositions
ATE500819T1 (de) 2003-12-31 2011-03-15 Bend Res Inc Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren
JP2005213763A (ja) 2004-01-27 2005-08-11 Yasushi Namihana ドア開閉補助装置
WO2005087208A2 (en) 2004-03-10 2005-09-22 Trustees Of Tufts College Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
US6946556B1 (en) 2004-05-21 2005-09-20 Acura Pharmaceuticals, Inc. Preparation of opioid analgesics by a one-pot process
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
ES2392645T3 (es) 2004-09-30 2012-12-12 Becton,Dickinson And Company Método para reducir o eliminar residuos en una recipiente médico de vidrio y recipiente hecho de acuerdo con el mismo
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
EP1845989A1 (en) 2005-01-20 2007-10-24 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
EP1901742A2 (en) 2005-06-03 2008-03-26 The University of Chicago Modulation of cell barrier dysfunction
US20080194611A1 (en) 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
EP1906838A4 (en) 2005-06-03 2008-10-08 Univ Chicago MODULATION OF MICROBIAL PATHOGENIC HOST CELL INTERACTIONS
US7935821B2 (en) 2005-06-09 2011-05-03 Mallinckrodt Inc. Method for separation and purification of naltrexone by preparative chromatography
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
EP1942903A4 (en) 2005-08-30 2011-01-12 Univ Kingston POTENTIATING THE THERAPEUTIC EFFECT OF AN OPIOID RECEPTOR AGONIST AND / OR INHIBITING OR REVERSING THE TOLERANCE FOR OPIOID RECEPTOR AGONISTS WITH A ULTRANOUS DOSE OF AN ALPHA-2 RECEPTOR ANTAGONIST
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20070259939A1 (en) 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
US20080075768A1 (en) 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200815451A (en) 2006-08-04 2008-04-01 Wyeth Corp 6-carboxy-normorphinan derivatives, synthesis and uses thereof
WO2008021394A2 (en) 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
TW200817048A (en) 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
MX2009005463A (es) 2006-11-22 2009-08-28 Progenics Pharm Inc Proceso para sintetizar analogos cuaternarios de 4,5-epoxi-morfinano y aislar sus n-estereoisomeros.
EP2101774A2 (en) 2006-11-22 2009-09-23 Progenics Pharmaceuticals, Inc. 7,8-saturated-4,5-epoxy-morphinanium analogs
BRPI0719327A2 (pt) 2006-11-22 2014-02-04 Progenics Pharm Inc N-óxidos de análogos de 4,5-epóxi-morfinano
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
EP2565195B1 (en) 2007-03-29 2015-05-06 Wyeth LLC Peripheral opioid receptor and antagonists and uses thereof
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
JP2011519930A (ja) 2008-05-07 2011-07-14 ネクター セラピューティクス 末梢性オピオイドアンタゴニストの経口投与
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN101845047B (zh) 2009-12-31 2011-12-07 南京臣功制药有限公司 一种溴甲基纳曲酮的制备方法
CN102918039B (zh) 2010-03-11 2017-06-09 惠氏有限责任公司 甲基纳曲酮的口服制剂和亲脂盐
KR20140107540A (ko) 2011-12-19 2014-09-04 샐릭스 파마슈티컬스 리미티드 메틸날트렉손의 경구 조성물을 사용하는 오피오이드 유발성 변비의 치료 및 예방 방법
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
MX2021013488A (es) 2019-05-07 2021-12-10 Bausch Health Ireland Ltd Formulaciones liquidas de dosis oral de metilnaltrexona.

Also Published As

Publication number Publication date
US20230414490A1 (en) 2023-12-28
TW200815007A (en) 2008-04-01
AR063471A1 (es) 2009-01-28
IL194182A (en) 2013-08-29
NZ597260A (en) 2013-07-26
BRPI0708965B1 (pt) 2020-01-07
SG174030A1 (en) 2011-09-29
AU2007281984B8 (en) 2014-01-09
TWI489984B (zh) 2015-07-01
JP5356231B2 (ja) 2013-12-04
PE20080741A1 (es) 2008-08-06
AU2007281984A1 (en) 2008-02-14
CN101405031B (zh) 2012-10-10
NO343701B1 (no) 2019-05-13
CN101405031A (zh) 2009-04-08
ECSP088752A (es) 2008-10-31
GT200800185A (es) 2009-08-27
US20100249169A1 (en) 2010-09-30
BRPI0708965A2 (pt) 2011-06-28
RU2008138266A (ru) 2010-03-27
PH12013500801B1 (en) 2014-10-20
CN102846613A (zh) 2013-01-02
RU2539387C2 (ru) 2015-01-20
WO2008019115A2 (en) 2008-02-14
US20150025100A1 (en) 2015-01-22
AU2007281984B2 (en) 2013-12-05
US20080070975A1 (en) 2008-03-20
IL221795B (en) 2018-06-28
US20220023200A1 (en) 2022-01-27
US20160338946A1 (en) 2016-11-24
US20200179270A1 (en) 2020-06-11
JP2009545603A (ja) 2009-12-24
EP2046388B1 (en) 2017-12-13
ZA200808203B (en) 2010-06-30
WO2008019115A3 (en) 2008-07-03
IL221795A0 (en) 2012-10-31
PL2046388T3 (pl) 2018-04-30
CA2646901C (en) 2015-12-22
HN2008001464A (es) 2011-03-30
MX2008011993A (es) 2008-10-01
EP2046388A2 (en) 2009-04-15
NO20083973L (no) 2009-01-06
ES2655863T3 (es) 2018-02-22
KR20090040248A (ko) 2009-04-23
PH12013500801A1 (en) 2014-10-20
US12303592B2 (en) 2025-05-20
CA2646901A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
BRPI0708965B8 (pt) composição farmacêutica de metilnaltrexona
WO2007008704A3 (en) Melanocortin receptor ligands
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
ECSP088800A (es) Formulaciones de inhibidores de DPP IV
WO2008011071A3 (en) Interactions of hedgehog and liver x receptor signaling pathways
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
CR20140544A (es) Compuestos para inhibir la progresión mitotica
WO2008156677A3 (en) Cyclic peptide melanocortin receptor ligands
WO2009059048A3 (en) (+)-opioids and methods of use
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
WO2009152356A3 (en) Compounds and compositions useful for the treatment of malaria
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2009043889A3 (en) Oxadiazole derivatives
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
MX2011012366A (es) Mezclas fungicidas sinergeticas.
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
MX2010005589A (es) Composicion para el cuidado personal.
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
CL2009000281A1 (es) Compuestos derivados de 5,6-dihidro-pirrolo-[2,1-a]-isoquinolinas y pirrolo-[2,1-a]-isoquinolinas; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamaiento de trastornos de la fertilidad.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/08/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF